Mesenchymal Stem/Stromal Cells: ON DEMAND MANUFACTURING STRATEGY TO DELIVER MULTIPLE DOSES OF FRESHLY CULTURED UMBILICAL CORD DERIVED MSCS IN THE CELLULAR IMMUNO-THERAPY FOR COVID-19 RELATED ARDS CLINICAL TRIAL
间充质干细胞/基质细胞:按需生产策略,用于在 COVID-19 相关 ARDS 的细胞免疫疗法临床试验中提供多剂新鲜培养的脐带来源间充质干细胞
期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2020.571380
Guo, Meiying; Li, Wanlong; Li, Butuo; Zou, Bing; Wang, Shijiang; Fan, Bingjie; Sun, Xindong; Wang, Linlin; Khan, S; English, S; Hodgins, S; Lalu, M; Watpool, I; Champagne, J; Freund, D; Möbius, M Alexander; Rüdiger, M; Fergusson, D; Thébaud, B; Stewart, DJ; Courtman, DW